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P1. UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) SYSTEM IN
RECURRENT BREAST CANCER: ASSOCIATION WITH TAMOXIFEN
THERAPY
Meijer-van Gelder MEa, Look MPa, Peters HAa, Schmitt Mb, Bru¨nner Nc,
Harbeck Nb, Klijn JGMa, Foekens JAa. aErasmus-MC Rotterdam, Rotterdam,
The Netherlands; bFrauenklinik der Technischen Universitt, Mu¨nchen, Germany;
cRoyal Veterinary and Agriculture University, Frederiksberg, Denmark.
The urokinase system of plasminogen activation consists of four major
components, urokinase plasminogen activator (uPA), its receptor uPAR, and
its inhibitors, PAI-1 and PAI-2. The prognostic impact of the tumour levels of
these four factors is well established for patients with primary breast cancer,
especially for uPA and PAI-1 (Jnicke F, et al. J Natl Cancer Inst 2001, 93, Look
MP, et al. J Natl Cancer Inst 2002, 94). Furthermore, a predictive impact of UPA
and PAI-1 on adjuvant chemotherapy has recently been observed (Harbeck N,
et al. Cancer Res 2002, 62). Extending our earlier analyses on the predictive
impact of UPA and PAI-1 in recurrent breast cancer (Foekens JA, et al. J Natl
Cancer Inst 1995, 87), we addressed the predictive value of all four components
of the urokinase system with respect to the clinical beneﬁt patients with recurrent
breast cancer derive from tamoxifen therapy. The antigen levels of the factors
were determined by enzyme-linked immunosorbent analysis (ELISA) in cytosols
prepared from oestrogen receptor-positive primary breast tumours from 691
hormo-na patients with recurrent breast cancer and treated with tamoxifen as
ﬁrst-line systemic therapy. Increasing (log-transformed) tumour levels of uPA
and PAI-1 were signiﬁcantly related to a lower probability of clinical beneﬁt
from tamoxifen treatment. Analysing the factors as categorical variables showed
that high tumour levels of uPA (P<0.001), uPAR (P<0.01) and PAI-1 (P<0.01)
were associated with an unfavourable clinical beneﬁt. In the multivariable
analysis for clinical beneﬁt, uPA (P<0.001) provided additional information,
independent of the traditional predictive factors, including menopausal status,
steroid hormone receptor status, disease-free interval, and dominant site of
relapse. High tumour levels of uPA, uPAR, and PAI-1 also predicted a shorter
progression-free survival after start of tamoxifen therapy in a time-dependent
analysis.
However, high PAI-2 levels (P=0.015) were related to a prolonged time of
clinical beneﬁt in the analysis without time-restriction. In conclusion, all four
components of the uPA-system were predictive for the eﬃcacy of tamoxifen
treatment in patients treated for recurrent breast cancer. The role these four
factors may play in tumour growth and metastasis might not only provide
valuable information for the individualisation of adjuvant therapy for patients
with primary breast cancer, but also for the design of novel, targeted
(combination) therapies for patients with recurrent breast cancer.
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P2. EXPRESSION OF IMMUNOHISTOCHEMICAL OESTROGEN
RECEPTORS a AND b IN ENDOMETRIAL CARCINOMA
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Introduction: Endometrial cancer, (EC) is the most common female genital track
malignancy in European countries. EC is known to be an oestrogen-dependent
disease. Oestrogens exert very powerful eﬀects on the growth, diﬀerentiation and
function of many target tissues, such as female reproductive organs, and are
known to stimulate cellular proliferation in the uterus. Two oestrogen receptor
types, named ERa and ERb [1], have been identiﬁed as the chief mediators of the
diverse biological functions of oestrogen and play an important role in
oestrogen-dependent tissues and cancers [2,3]. The aim of the present study
was to evaluate ERa and ERb protein expression in normal and neoplastic
endometrium in relation to histopathological and clinical data according to the
World Health Organisation (WHO) and The International Federation of
Gynaecology and Obstetrics (FIGO) 1988 criteria.
Material and Methods: Samples of normal endometrium and endometrial cancer
tissue were collected from women, 14 normal endometrium (7 from proliferative
and 7 from secretive phase) and 21 malignant samples (8 Grade (G)1, 7 G2 and 7
G3; stages of diﬀerentiation) according to the WHO classiﬁcation. ERa and ERb
immunohistochemical analysis was performed on each paraﬃn-embedded block
(5-m sections) and on adjacent sections stained previously with 1D5 ERa
monoclonal antibodies (Dako Corp Carpintiera) using the chicken polyclonal
ERb503 IgY. Immunostaining was revealed using a streptavidin–biotin-en-
hanced immunoperoxidase technique. After antigen retrieval by pressure
cooking in 0.1 M ethylene diamine tetraacetic acid (EDTA) buﬀer (pH 7.2)
for 10 min and endogenous peroxidase blocking with 1% H202, sections were
incubated with normal donkey serum (1:40 dilution) in phosphate-buﬀered
solution (PBS) for 30 min at 22 C. Sections were then incubated overnight at
4C with ERb 503 IgY (1:1250 dilution). The complex was revealed using an
anti-chicken biotinylated antibody (1:300 dilution; Vector) and streptavidin–
peroxidase complex (1:1000 dilution; Dako Corp Carpintiera USA). 3,3
Diaminobenzidine tetrahydrochloride (Sigma) was used as the chromogen and
the samples were counterstained with haematoxylin (Dako), dehydrated and
mounted. The oestrogen receptors were counted on a semiquantitative scale
from 1+ to 3+.
Results: In the samples of normal and neoplastic endometrium examined, the
expression of ERa and ERb diﬀered between normal endometrial and cancer
tissues. We observed a strong reaction for ERa in normal and neoplastic
endometrium, whereas only a very slight reaction to ERb was observed.
Conclusions: Our results demonstrate that ERa is a predominant form of
oestrogen receptor in the human uterus and diﬀerential ERa and ERb expression
may play an important role in endometrial carcinogenesis and be useful
information when deciding upon hormonal treatment for endometrial cancer [4].
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P3. EXPRESSION OF OESTROGEN RECEPTOR BETA VARIANTS AND
PROGESTERONE RECEPTOR ISOFORMS IN ENDOMETRIAL
CANCER
Sakaguchi H, Fujimoto J, Bao LH, Tamaya T. Gifu University School of
Medicine, Gifu City, Japan
Oestrogen is recognised as an important modiﬁer in the development, growth
and invasiveness of endometrial cancer (EC). Progesterone is antagonistic to
oestrogen-mediated cell proliferation and is the principal hormone that
promotes diﬀerentiation in endometrium. Among the various factors, the
expression patterns of sex steroid receptors, such as oestrogen receptor (ER) and
progesterone receptor (PR) are extremely important with regard to patient
prognosis [1]. In our previous reports, we described the characteristic expression
pattern of ER alpha (ERa) and ER beta (ERb) in EC [2], endometriosis [3],
myometrium [4] and ovarian cancer [5]. We recognise that the intact synchron-
ised expression of ERb interacting with ERa might be disrupted in most
metastases of uterine endometrial cancers, leading to advancement and poor
patient prognosis with refractoriness of hormone treatments. A novel C-terminal
splice variant of ERb, named ERb2, was reported in 1998. ERb2 does not bind
E2 and is a dominant-negative regulator of ERa. In order to evaluate the
respective contribution of ERb and PR isoforms in EC, we quantiﬁed the
absolute expression levels of ERa, ERb1 (wild-type), ERb2, along with total
progesterone receptor (PR)-AB, and PR-B, the B isoform of PR by real-time
quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assays
with recombinant RNAs as standards in 60 EC and 21 normal endometria (NE).
We then analysed the correlation between expression levels of each receptor and
clinical characteristics including patients’ prognoses. The expression of ERb2,
but not of ERb1, was signiﬁcantly, positively correlated to that of ERa and PR-
B in EC. In addition, levels of ERb2, ERa and PR-B were signiﬁcantly decreased
in patients who died from EC compared with those who survived. As a result of
these changes, the ratio of ERb2 to ERa and the ratio of ERb1 to ERa
signiﬁcantly increased in EC patients who died over those who survived.
Interestingly, the ratios of ERb2 to ERa and ERb1 to ERa reﬂected patients’
prognoses better than levels of ERa or PR-B themselves. These results taken
together indicate that ERb2 may have a diﬀerent function from ERb1 and that
measurement of ERb2 has prognostic value in EC.
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P4. IUMPA-2 AS A MODULATOR OF THE EXPRESSION OF THE
OESTROGEN AND PROGESTERONE RECEPTORS IN ENDOMETRIAL
HYPERPLASIA SIMPLEX
Kowalski AJ, Welfel J, Suzin JI. Department of Gynaecological Oncology,
Medical University of Lodz, Lodz, Poland. Grant of The State Committee of
Scientiﬁc Research No. 4P05E 058 19
Introduction: Intrauterine medroxyprogesterone acetate (IUMPA-2) is an
intrauterine distribution system of medroxyprogesterone acetate (MPA), applied
in the treatment of endometrial hyperplasia simplex. The system contains 2 g of
MPA, of which a ﬁxed dose is released daily from the carrier over a period of 30
days. After completion of the process of releasing progesterone, the system
undergoes an automatic biodegradation and therefore does need not be removed
from the uterus. The objective of this study was to examine the inﬂuence of
IUMPA-2 on cell protein synthesis in endometrial hyperplasia simplex tissue
and, as a consequence, its antiproliferative eﬀect. The cytosolic receptor level was
established as a marker of the decrease in intracellular protein synthesis. We
have demonstrated a relationship between the levels of both of these receptor
proteins and cell proliferation.
Patients and methods: The study comprised 54 (female) patients in whom
endometrial hyperplasia simplex was diagnosed. They underwent a standard, 30-
day treatment with application of IUMPA-2. Histopathological material was
acquired on two occasions: during the installation of the therapeutic system and
7 days after treatment completion. On both occasions, hysteroscopic-guided
biopsy was performed, with the invariant size of the sample being 2 mg. The
cytosolic level of both oestrogen and progesterone receptors was measured using
an immunoenzymatic method in order to assess the receptor protein level in
relation to the total protein level in the tissue examined (fmol/mg).
Results: Levels of cytosolic oestrogen receptor:
• before treatment: 221.52 fmol/mg (SD 96.42),
• after treatment: 49.33 fmol/mg (SD 26.87).
Levels of cytosolic progesterone receptor:
• before treatment: 614.29 fmol/mg (SD 252.31),
• after treatment: 198.49 fmol/mg (SD 62.37).
Discussion: In contrast to previous research concerning the eﬃciency of use of
IUMPA-1 in the growth inhibition of endometrial carcinoma, a several-fold
larger inhibition of marker protein production was observed in tissues exhibiting
endometrial hyperplasia. It appears to be caused by a higher initial level of the
progesterone receptor in the tissues aﬀected by endometrial hyperplasia.
Conclusions:
(1) IUMPA-2 has a modulating eﬀect on the cytosolic levels of oestrogen and
progesterone receptors in endometrial hyperplasia simplex.
(2) IUMPA-2 inhibits the synthesis of cell proteins, thereby inhibiting the
proliferation of the tissue aﬀected by endometrial hyperplasia simplex.
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P5. THE VALUE OF TRANSVAGINAL ULTRASONOGRAPHY IN
PREDICTING ENDOMETRIAL PATHOLOGIES IN ASYMPTOMATIC,
POSTMENOPAUSAL, TAMOXIFEN-TREATED BREAST CANCER
PATIENTS
Cohen I, Markovitz O, Tepper R, Aviram R, Fishman A, Shapira J. Department
of Obstetrics and Gynecology, Sapir Medical Center, Kfar-Saba, Israel
Purpose: There is no established ultrasonographic endometrial cut-oﬀ value for
the diagnosis of endometrial pathologies in asymptomatic, postmenopausal,
tamoxifen-treated patients. We attempted to look for the most accurate cut-oﬀ
value.
Materials and methods: Multiple ultrasonographic cut-oﬀ points were evaluated
by logistic regression analysis, based on 279 patients who had transvaginal
ultrasonographic examinations and were followed by endometrial histopatho-
logical analysis. Performance characteristics were calculated and correlations
to endometrial histological ﬁndings assessed. Using the diﬀerent ultrasono-
graphic endometrial cutoﬀ values, a search was also made for potential cases of
various endometrial pathologies that could have been missed.
Results: There was a gradual increase in speciﬁcity and a gradual decrease in
sensitivity of the ultrasonographic studies with an increase in endometrial
thickness. More endometrial pathologies were identiﬁed with an increase in the
cut-oﬀ values. By using a cut-oﬀ value of 7.5 mm, we could have missed one case
(20.0%) of endometrial cancer, and the same principle was applied when a cut-oﬀ
value of 12.5 mm was used. However, with this latter cut-oﬀ value, we could have
avoided performing endometrial sampling in 59.1% of cases. With higher cut-oﬀ
values, more endometrial pathologies, including three more cases of endometrial
cancer, could have been missed, while more cases of endometrial sampling could
have been avoided.
Conclusion: In asymptomatic, postmenopausal, tamoxifen-treated breast cancer
patients, the use of higher endometrial cut-oﬀ values are associated with an
increased possibility of missing endometrial pathologies, including endometrial
cancers, while the amount cases of endometrial sampling may be reduced.
P6. DNA BINDING OF TAMOXIFEN IN HUMAN UTERINE AND COLON
TISSUE AFTER ADMINISTRATION OF A SINGLE 14C-LABELLED
THERAPEUTIC DOSE
Brown Ka, Martin EAb, Boocock Da, Farmer PBa, Dingley KHc, Ubick Ec,
Turteltaub KWc, Hemingway Dd, Al-Azzawi Fe, Parrott Ef, White INHf.
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UK; bAstraZeneca, Genetic Toxicology Department, Cheshire, SK10 4TG, UK;
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Tamoxifen, recently approved for the prevention of breast cancer in healthy
women, is known to increase the incidence of endometrial cancer and there is
some concern that tamoxifen therapy may be associated with an elevated risk of
colorectal malignancy. There is much controversy as to whether DNA adduct
formation is a contributing factor in tamoxifen-induced carcinogenesis in
women, since a genotoxic mechanism is known to occur in rat liver. The present
evidence is conﬂicting regarding whether tamoxifen adducts are formed in
human tissues. We have therefore employed the sensitive technique of acceler-
ator mass spectrometry to unequivocally determine if 14C-tamoxifen DNA
adducts are detectable in uterine and colon tissue of patients administered a
single therapeutic dose of 14C-radiolabelled drug (20 mg, 1.85 MBq) 18 h prior to
hysterectomy or colorectal surgery, respectively.
Quantitation of 14C-radiolabel in tissues conﬁrmed the presence of tamoxifen
and its metabolites at a concentration of 204 ± 23 fmoles (mean ± standard
error of the mean (SE), n = 10) and 653 ± 135 fmoles (n = 10) tamoxifen
equivalents/mg in uterine and colon tissue, respectively. Following this single
dose, plasma levels of tamoxifen equivalents at the time of surgery were
comparable in the two patient populations (19 ± 2 ng/ml, n = 20) and similar to
published values. We demonstrate that tamoxifen does bind irreversibly to DNA
from both the uterus and colon of treated patients, with the extent of damage
detected being 237±77 DNA adducts/1012 nucleotides in uterine endometrium
and 4356 ± 1050 adducts/1012 nucleotides in colon tissue. Similar levels were
present in the myometrial layer, a tissue in which tumours do not arise as a
consequence of tamoxifen treatment. In colon, the levels of CYP3A4 protein, the
enzyme responsible for conversion of tamoxifen to a reactive electrophile were
10-fold higher than those detected in uterine tissue of untreated patients
(1.01 ± 0.14 pmols/mg protein (n = 10) compared with 0.10 ± 0.03 (n = 4)), but
did not correlate with levels of DNA binding. These results show conclusively
that tamoxifen is able to bind to human uterine and colon DNA, but the extent
of DNA damage is 4–5 orders of magnitude below that detected in rats that
develop liver tumours after chronic tamoxifen treatment. The role of this low
level of damage and the importance of alternative epigenetic mechanisms in the
development of tamoxifen-induced cancer remains to be determined.
P7. EFFECTS OF TIBOLONE ON OESTROGEN AND PROGESTERONE
RECEPTOR EXPRESSING HUMAN ENDOMETRIAL CANCER CELL
LINES
Leen J Bloka, Payman Haniﬁ Moghaddama, Helenius J Kloosterboerc, Heidy
van Wijk Fb, Curt W Burgerb. aDepartment of Reproduction & Development,
Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands; bDepart-
ment of Gynecology & Obsterics, Erasmus MC, P.O. Box 1738, 3000 DR
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Tibolone is a tissue-speciﬁc compound used for treatment of climacteric
complaints and prevention of osteoporosis. It is converted by steroid metabol-
ising enzymes in the liver and intestine into three active metabolites: d-4-isomer
(exerting progestagenic and androgenic eﬀects) and two hydroxy-metabolites:
3-OH-tibolone and 3-OH-tibolone (exerting oestrogenic eﬀects). The aim of the
current study was to gain more insight into the progestagenic, oestrogenic and
tibolone-speciﬁc eﬀects on the endometrium, using human endometrial cancer
cell lines expressing diﬀerent amounts of steroid receptors.
The following cell lines were used:
• Parental Ishikawa cells: progesterone receptor (PR)- and oestrogen receptor
(ER)-negative.
• PRAB-36 cells (Ishikawa sub-cell line): PRA- and PRB-positive, ER-negative.
• ECC1: PR-negative, ER-positive.
• ECC1-AB21 (ECC1 sub-cell line): PRA-, PRB- and ER-positive.
The cells were cultured for 10 days in the presence or absence of tibolone (100
nM), metabolites of tibolone (100 nM), medroxyprogesterone acetate (MPA) (1
nM), E2 (1 nM) or MPA+E2, before growth was measured, or morphology
assessed. The molecular mechanism underlying the counterbalancing eﬀect
between the progestagenic and oestrogenic activities of tibolone will, in the near
future, be studied using microarrays.
Growth experiments showed tibolone-induced growth inhibition in progester-
one-responsive endometrial carcinoma cells; tibolone-induced growth-stimula-
tion in oestrogen-responsive endometrium carcinoma cells; and, interestingly, in
endometrial cell lines expressing both PR and ER, tibolone and the combination
of E2+MPA, inhibited growth. Upon reviewing the morphology of the cells, it
was observed that progestagens induced ﬂattening of the cells in a single layer,
while oestrogens induced growth in multiple layers. Culture in the presence of
tibolone, or E2+MPA, veriﬁed in PR- and ER-expressing ECC1–AB21 cells, was
observed to be undistinguishable from culturing in the presence of MPA alone.
These results indicate that, in endometrial cancer cell lines expressing both ER
and PR, the oestrogenic, growth-stimulating, properties of tibolone are
eﬀectively counterbalanced by its progestagenic, growth inhibiting properties.
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P9. IMMUNOHISTOCHEMICAL PROFILE OF ENDOMETRIAL BIOP-
SIES FROM PATIENTS TREATED WITH LHRH AGONISTS AND
TAMOXIFEN REFLECTS THE ANTIPROLIFERATIVE PROPERTIES
OF LHRH AGONISTS
Galant C, Marbaix E, Piette P, Machiels JP, Duck L, Donnez J, Berlie`re M.
Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium
We previously presented the results of a prospective study [1] conducted with
postmenopausal breast cancer patients receiving a combination of luteinising
hormone-releasing hormone (LHRH) agonists (goserelin (Zoladex) 3.6 mg,
monthly) and tamoxifen (Nolvadex 20 mg, daily) as adjuvant therapy. The aim
of the present study was to investigate the safety proﬁle of this combined
treatment on the endometrium. Among the 85 patients screened, no benign or
atypical endometrial lesions were observed. The mean duration of the follow-up
was 3.7 years. The combination of LHRH agonists and tamoxifen prevents
endometrial growth induced by tamoxifen. With the agreement of the patients,
hysteroscopies and endometrial biopsies were performed after at least 3 years of
therapy. To try to explain the remarkable protection of the endometrium by
LHRH, we compared the immunohistochemical proﬁle of Ki67 (clone MIB1,
Dako) and p53 (clone DO-7, Dako) in endometrial biopsies collected from
women on the combined therapy and on tamoxifen alone. All endometrial
biopsies from patients on the combined treatment presented an atrophic
endometrium at histological examination and showed no immunostaining for
Ki67 and p53. In contrast, a nuclear immunostaining of Ki67 and of p53 was
noticed in the endometrium of patients treated with tamoxifen alone, irrespective
of the histological appearance of the endometrium, as well as in the proliferative
endometrium from premenopausal women who were used as controls. These
results show that LHRH agonists have an antiproliferative eﬀect that explains its
growth inhibitory action on the endometrium [2,3].
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P10. COMBINED ADMINISTRATION OF ANASTROZOLE, 5-DEOXY-
AZACYTIDINE AND VINORELBINE-TARTRATE INDUCE THE D2
STAGE OF APOPTOSIS IN AN ADVANCED BREAST INFILTRATING
DUCTAL CARCINOMA CHARACTERISED BY OVEREXPRESSION OF
BCL-2, 5’CPG ISLAND HYPERMETHYLATION OF THE AROMATASE
(CYP19) GENE AND ER
Giannios Ja, Xepapadakis Gb. aDepartment of Oncology, GSHA. bDepartment of
Breast Surgery, MH, ATH, Gr, EU
Postmenopausal women produce oestrogens through the aromatase (CYP19)
gene which is present in high concentrations in breast cancer tissue and its
stroma. Anastrazole is a reversible aromatase inhibitor which interrupts the
metabolic transformation of androgenic precursors into oestrogens inhibiting its
production within the tumour deposit. This mechanism makes aromatic
inhibitors, such as anastrozole, superior to other endocrine therapies. Although
breast cancer is sensitive to endocrine intervention in sequence, eventually
resistance will occur. We obtained cancer cells from a treatment-resistant post-
menopausal patient with advanced inﬁltrating or invasive ductal carcinoma
(IDC). Methylation-speciﬁc polymerase chain reaction (MSP) detected coinci-
dent aberrant 5’CpG island hypermethylation of aromatase (CYP19) and
oestrogen receptor (ER) which caused their transcriptional silencing. Loss of ER
and CYP19 expression was associated with poor histological diﬀerentiation, high
growth fraction and poor clinical outcome. Polymerase chain reaction (PCR)
exhibited overexpression of anti-apoptotic oncogene, bcl-2, which causes
chemoresistance. After combined administration with the aromatase inhibitor
anastrozole, DNA methyltransferase inhibitor 5-deoxyazacytidine and microtu-
bule depolymerising agent vinorelbine-tartrate, we observed phosphorylation
and downregulation of bcl-2, CpG island demethylation and re-expression of
CYP19 and ER protein and inhibition of the metabolic transformation of
androgenic precursors into oestrogens. All of these events induced apoptosis in
the tumour cells as measured by TdT-mediated-DUTP-biotin nick-end labelling
(TUNEL). Furthermore, transmission electron microscopy showed irreversible
D2 apoptotic signs, such as the disintegration of tumour cells to membrane-
bound small bodies (apoptotic bodies) which were phagocytosed by adjacent
tumour cells leading to a bystander killing eﬀect. In conclusion, this therapeutic
approach may revolutionise treatment against advanced breast inﬁltrating ductal
carcinomas that are resistant to treatment due to the potential advantages
oﬀered in comparison to conventional therapy. These include a well deﬁned
mode of action, selectivity and the circumvention of resistance to treatment.
P8. EXPRESSION OF IMMUNOHISTOCHEMICAL OESTROGEN
RECEPTORS a AND b IN OVARIAN CANCER TISSUE
Skrzypczak Ma, Szymczak Sb, Radwanska Kb, Szczylik Kd, Karczmarek Lb,
Sasor Af, Jakowicki JAa, Warner Mc, Gustafsson JAc,e. aDepartament of
Gynaecology, University School of Medicine, Jaczewskiego St. 8, 20-954 Lublin,
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Pasteura 3, 02-093 Warsaw, Poland; cDepartments of Medical Nutrition and
Biosciences, Karolinska Institute Novum, S-141 86 Huddinge, Sweden; dDepart-
ment of Oncology, Military Institute of Medicine, Szaserw St. 128, 00-909
Warsaw, Poland; eDepartment of Biosciences, Karolinska Institute Novum, S-141
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Introduction: In European countries, epithelial ovarian cancers (EOC) are a
common cause of death from gynaecological malignancies, but little is known
about the oestrogen dependency of EOC. Oestrogens have eﬀects on the growth,
diﬀerentiation and function of many target tissues, such as female reproductive
organs, and especially in the ovaries and ovarian cancer tissues. ERb is the
predominant form in human ovaries [1,2]. The aim of this study was to evaluate
ER-a and ER-b expression in ovarian cancer.
Material and methods: Samples of ovarian cancer tissue were collected from
women; 70 samples of ovarian epithelial cancers were examined for the presence
of ERa and 17 ovarian cancers for the presence of ER-b. ERa and ERb
immunohistochemical analysis was performed on each paraﬃn-embedded block
(5-m sections) and on adjacent sections stained previously with 1D5 ERa´
monoclonal antibodies (Dako Corp Carpintiera) using the polyclonal ER
(Upstate Corp.). Immunostaining was revealed by a streptavidin–biotin-
enhanced immunoperoxidase technique. After antigen retrieval by pressure
cooking in 0.1 M ethylene diamine tetraacetic acid (EDTA) buﬀer (pH 7.2) for
10 min and endogenous peroxidase blocking with 1% H02, sections were
incubated with normal donkey serum (1:40 dilution) in phosphate-buﬀered
solution (PBS) for 30 min at 22 C. Sections were then incubated overnight at 4
C with ER (1:1250 dilution). The complex was revealed using anti-chicken
biotinylated antibody (1:300 dilution; Vector) and streptavidin–peroxidase
complex (1:1000 dilution; Dako Corp Carpintiera, USA). 3,3 Diaminobenzidine
tetrahydrochloride (Sigma) was used as the chromogen and the samples were
counterstained with haematoxylin (Dako), dehydrated and mounted. The
oestrogen receptors were counted on a semiquantitative scale from 1+ to 3+.
Results: In the ovarian cancer samples examined, more than 60% showed
expression of ER-a. ERb was observed in more than 90% of EOC.
Conclusion: Our preliminary results reveal that ER-a and ERb expression
in ovarian cancer tissues. ER and ER expression may play an important role in
ovarian carcinogenesis and be useful in the early diagnosis and treatment of
ovarian cancers [3,4,5].
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P11. POTENT PHYTO-OESTROGENICITY OF 8-PRENYLNARINGENIN
AND CANCER-CHEMOPREVENTIVE ACTIVITY OF XANTHOHUMOL,
PRENYLATED FLAVONOIDS DERIVED FROM HOPS (HUMULUS
LUPULUS L.)
Heyerick A, De Keukeleire D. Ghent University, Faculty of Pharmaceutical
Sciences, Laboratory of Pharmacognosy and Phytochemistry, Ghent, Belgium
8-Prenylnaringenin, a prenylated ﬂavanone, has been identiﬁed as the oestro-
genic principle of hops (Humulus lupulus L.) [1]. Based on speciﬁc and sensitive in
vitro bioassays (Ishikawa Var-I, yeast oestrogen screen, receptor binding), 8-
prenylnaringenin proved to be a highly potent phyto-oestrogen with oestrogenic
acitivities considerably greater than that of other well-established phyto-
oestrogens such as coumestrol, genistein, and daidzein [1]. The oestrogenic
activity was conﬁrmed by in vivo assays with ovariectomised mice and rats (acute
uterine vascular response, vaginal mitosis, uterine response, bone protective
eﬀect) after subcutaneous or oral administration [2,3]. Xanthohumol, a
prenylated chalcone, is oestrogenically inactive, but was shown to have high
cancer-chemopreventive properties in vitro at all stages of carcinogenesis
including a strong anti-proliferative activity [4,5].
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P12. BODY FAT DISTRIBUTION AFFECTS STEROID RECEPTOR
EXPRESSION IN BREAST CANCERS FROM POSTMENOPAUSAL
WOMEN AND MAY PREDICT PROGESTERONE RECEPTOR (PR)
EXPRESSION IN THOSE WITH AN OESTROGEN RECEPTOR
(ER)-POSITIVE LESION
Leunen K, Van Mieghem T, Huang HJ, DeLeyn A, Amant F, Berteloot P,
Paridaens R, Drijkoningen M, Christiaens MR, Vergote I, Neven P. Multidis-
ciplinary Breast Centre. UZLeuven, Herestraat 49, Leuven, Belgium
Background: Approximately 1 in three ER-positive breast cancers diagnosed
after the menopause is PR-negative. PR is an end-product of the nuclear
oestrogen–oestrogen receptor binding. Furthermore, postmenopausal oestrogens
are from the aromatisation of adrenal androgens in peripheral fat tissue. We
evaluated the eﬀect of parameters reﬂecting body fat and body fat composition
on ER and PR-expression in postmenopausal women with breast cancer.
Patients and methods: Between January 1st, 2002 and September 2003, 390
postmenopausal women with a primary operable breast cancer were evaluated
upon admission for body weight, height, abdominal and hip circumference.
Waist-to-hip ratio (WHR) and BMI [Weight/(Length in metres)2] were calcu-
lated. We compared mean values for BMI and WHR between ER and PR and
for their combined expression. Tumours with an ER-PR+ phenotype (n = 3)
were excluded. For all breast cancers and for those with an ER-positive lesion,
we compared the frequency of PR positivity for those in the lowest (Q1) and
those in the highest quartile (Q4) of BMI and WHR, respectively. We also aimed
to estimate the number of patients to include in order to show a statistical
diﬀerence (P < 0.05) if the percentage of PR positivity in those that are ER-
positive does not change. For steroid measurements, we used the H-score and
deﬁned steroid receptor-negativity for ER and PR as a value of <100/300.
Results: When the total number of patients reaches 468 and the current
percentage for PR-positivity in those who are ER-positive does not change,
WHR may signiﬁcantly predict PR positivity in women with an ER-positive
breast cancer comparing Q1 with Q4 (see Table 1–3).
Conclusion: Although mean values for BMI are not diﬀerent between postmen-
opausal breast cancers with a diﬀerent steroid receptor expression pattern, mean
WHR predicts ER, PR and the combination. In women with an ER-positive
breast cancer, we see a trend for WHR to predict PR-expression, but larger
numbers are required before this is likely to reach signiﬁcance.
Table 1
BMI and WHR according to ER and PR level (mean ±SD)
ER 0-100 ER 100–300 P-value PR 0–100 PR 100–300 P-value
N 79 311 195 195
BMI 26.4 ± 5.5 26.6 ± 4.5 0.703 26.9 ± 4.8 26.3 ± 4.9 0.225
WHR 0.88 ± 0.74 0.91 ± 0.09 0.026 0.91 ± 0.09 0.89 ± 0.04 0.065
N, number; SD, standard deviation. See text for other deﬁnitions.
Table 2
BMI and WHR according to ER/PR (mean ± SD)
ER – PR– ER+PR– ER+PR+ P-value
N 73 122 192
BMI 26.6±5.5 26.2±4.4 26.9±4.8 0.395
WHR 0.89±0.07 0.90±0.09 0.91±0.08 0.069
Table 3
PR positivity (%) in all patients and in those with an ER-positive tumour per quartile (Q)1 and Q4 for BMI and WHR
All Q1 Q4 P-value ER+ Q1 Q4 P-value
N 97 97 N 79 79
BMI 45.4% 51.5% 0.473 BMI 55.8% 61.5% 0.516
WHR 45.4% 58.8% 0.084 WHR 57.1% 67.9% 0.186
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P13. IL-1 SYSTEM AND SEX STEROID RECEPTOR EXPRESSION IN
HUMAN BREAST CANCER: IL-1a PROTEIN SECRETION IS CORRE-
LATED WITH MALIGNANT PHENOTYPE
Christian F. singera,b, Nicole Kronsteinera, Gernot Hudelista, Erika Martona,
Ingrid Walterc, Marion Kubistaa, Klaus Czerwenkab, Martin Schreibera,
Kubista Ea.aDivision of Special Gynecology and Ludwig-Boltzmann-Institute of
Clinical Experimental Oncology, University of Vienna Medical Center, 1090
Vienna, Austria;bDepartment of Pathology, University of Vienna Medical Center,
1090 Vienna, Austria;cDepartment of Histology and Embryology, University of
Veterinary, 1210 Vienna, Austria
Purpose: The interleukin-1 (IL-1) system plays an important role in human
pathology and is involved in the local control of malignant disease. However,
little is known about its expression in breast cancer and its correlation with
prognostic parameters, such as receptor status and grading.
Experimental design: The expression of IL-1a and other IL-1 family members
was analysed by reverse transcriptase-polymerase chain reaction (RT-PCR),
enzyme-linked immuno-sorbent assay (ELISA) and immunohistochemistry in
breast cancer cell lines, tumour-derived ﬁbroblasts, and breast cancer tissue
biopsies, and compared with sex steroid receptor status and grading.
Results: In breast cancer cell lines, IL-1a and b gene expression was present in
the phenotypically most malignant cell lines, whereas ERa and PR mRNA
expression was conﬁned to lines that exhibit a rather benign phenotype. Only the
highly malignant receptor-negative tumour cell line, MDA-MB 231, expressed
IL-1a protein, and none of the cell lines secreted IL-1b. Breast cancer tissues
expressed various amounts of IL-1a, IL-1b and IL-1 Ra mRNA, but consistently
high levels of IL-1tIR. IL-1a protein expression was detected in tumour cells
and/or adjacent stroma in 88%, and epithelial protein expression was correlated
with both, increasing de-diﬀerentiation (P = 0.002; r = 0.469), and decreasing
epithelial ERa expression in the neighbouring tumour epithelium (P = 0.001;
r = 0.457).
Conclusion: We have demonstrated the presence of a functional IL-1 system in
breast cancer and found that IL-1a is inversely correlated with local sex steroid
receptor expression. We hypothesise that the unphysiological expression of IL-
1a in less diﬀerentiated and ERa-tumours might contribute to their local
invasiveness and malignant behaviour.
P15. SOME PECULIARITIES OF THE INFLUENCE OF TAMOXIFEN ON
THE ENDOMETRIUM OF POST-MENOPAUSAL PATIENTS
Ashraﬁan LA, Antonova IB, Albitskiy IA, Mozkobili TA, Chazova NL. Russian
Scientiﬁc Centre of Roentgen-Radiology, Moscow, Russia
The aim of our research was to study the inﬂuence of tamoxifen on the
endometrium, in post-menopausal patients, and to perform an hyperplastic
processes during therapy. Two groups of patients were formed: 155 received
tamoxifen for more than 1 year (the study group) and 121 did not receive anti-
oestrogen therapy (the controls). The groups were standard with regard to their
age, duration of postmenopause, time to beginning of the postmenopause and
co-morbid diseases. Investigations were supported by anamnesis, transvaginal
sonography, hysteroscopy with aspirate biopsy in cases of increasing M-echo of
more than 5 mm and morphological analysis of bioptate. Results in the study
group showed an increasing M-echo in 95 (61%) patients, hyperplasic processes
were found using hysteroscopy among 43 (28%) of patients and 31 (20%) of them
had ﬁbrotic polyps and 12 (8%) – adeno-cystosis hyperplasia. In 49 (32%) of
cases atrophy of the endometrium was found, but morphological investigations
showed hyperplasia in the basal part of endometrium, with large amounts of
sclerosing spiral arteries. Three (2%) patients had endometrial adenocarcinoma
with a high level of diﬀerentiation status. In the control group, 22 (18%) had an
increased M-echo and 20 (17%) of them had hyperplastic processes that
consisted of 7 (6%) polyps, 11 (9%) adenohyperplasia and 2 (2%) atypical
hyperplasia. Two (2%) patients had highly diﬀerentiated adenocarcinoma of the
endometrium. In conclusion, tamoxifen causes proliferation of the stromal
component and hyperplasia of the basal part of the endometrium, as can be seen
by an increasing M-echo. The most frequent consequences of basal hyperplasia
are ﬁbrotic polyps of the endometrium.
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P14. TIBOLONE AND ITS METABOLITES INHIBIT THE INVASION OF
HUMAN MAMMARY CANCER CELLS
Bracke ME a, Vanhoecke BW b, Depypere HT b, Kloosterboer HJ c. aLaboratory
of Experimental Cancerology, Ghent University, Gent; bDepartment of Gynaeco-
logical Oncology, Ghent University, Gent; cOrganon NV, Oss, The Netherlands
Invasion of mammary cancer cells leads to metastasis and is the major
determinant of the fatal outcome of the disease. Since tumours are considered as
micro-ecosystems consisting not only of cancer cells, but also of living and non-
living host elements, invasion models oﬀering living tissue as a confronting
partner for the test cancer cells are more relevant to tumour behaviour in vivo
than models oﬀering non-living host material only. So, in addition to the
collagen type I invasion assay, we also include the chick heart assay as a model
to evaluate the eﬀect of possible anti-invasive agents. For tibolone and its
metabolites, collagen type I gels were incubated with human T47-D mammary
carcinoma cells, while embryonic chick heart fragments were confronted with
human MCF-7/6 mammary cancer cells. The interaction of the cancer cells with
their substrates was evaluated in living cultures after 1 day and on histological
sections after 8 days. At 100 lM, tibolone and its 3-b-OH metabolite inhibited
invasion of T47-D cells into collagen type I, while in this assay 3-a-OH,
sulphated 3-a-OH and d 4 failed to do so. In the chick heart assay, tibolone and 3
of its metabolites (3-a-OH, 3-b-OH and d 4) inhibited invasion of MCF-7/6 cells.
In the latter assay, the treated cancer cells were found to grow around the chick
heart fragment without any signs of occupation or destruction of the host tissue.
Among the many hundreds of compounds tested during recent years in the chick
heart assay, tibolone and its principal metabolites share their anti-invasive eﬀect
with tamoxifen, retinoic acid, the citrus ﬂavone tangeretine and the hops-derived
prenylated chalcone xanthohumol. The mechanism of action of tibolone and its
metabolites is now under study, and we can already exclude eﬀects on directional
migration and on cell-cell adhesion. In conclusion, tibolone and 3-b-OH tibolone
possess anti-invasive activities in at least two diﬀerent invasion assays using
human mammary carcinoma cells. This may add to the beneﬁcial eﬀects of
tibolone in cancer patients.
Vanhoecke BW is a recipient from the Gent University (BOF nr. B/00222/01).
P16. DISSEMINATION OF PROBAND-MEDIATED INFORMATION
DOES NOT MEET THE EXPRESSED WISHES OF FAMILIES WITH A
BRCA1/2 GENE MUTATION
Sermijn Ea,b, Goelen G
a,c, Teugels Ea,d, Kaufman L
e
, Bonduelle M
a,f
, Neyns
Ba,b,d, De Gre`ve Ja,b,c,d. aFamily Cancer Clinic, AZ-VUB, Vrije Universiteit
Brussel, Laarbeeklaan 101, B-1090 Jette, Belgium; bDepartment of Medical
Oncology, AZ-VUB, Vrije Universiteit Brussel, Belgium; cDepartment of Cancer
Prevention, AZ-VUB, Vrije Universiteit Brussel, Belgium; dDepartment of
Molecular Oncology, AZ-VUB, Vrije Universiteit Brussel, Belgium; eDepartment
of Medical Statistics, AZ-VUB, Vrije Universiteit Brussel, Belgium. fDepartment
of Medical Genetics, AZ-VUB, Vrije Universiteit Brussel, Belgium
Background: Genetic counselling for hereditary breast and/or ovarian cancer
(HBOC) is usually based on a protocol of non-directive counselling from the
international guidelines used for Huntington families. When a BRCA1/2 gene
mutation is found in a family, the possibility of predictive counselling and testing
is also oﬀered to the other family members, but only through informing the
proband. We have examined the eﬃciency of information transfer from the
proband to the other relatives, and we compared the level of transferred
information to the needs in these families.
Patients and methods: Fourteen families (with a BRCA1/2 mutation) with 107
subjects participated in the study. Subjects were eligible for participation if they
were ﬁrst-degree relatives of an aﬀected person with breast cancer, ovarian
cancer, or another primary cancer, or if they were ﬁrst-degree relatives of a
known or probable mutation carrier. Data were collected using semi-structured
interviews.
Results: This study clearly reveals that the transfer of information from
probands to their relatives is highly defective. In contrast, and surprisingly,
almost all participating relatives (97.8%) wanted to be informed about the
various aspects concerning HBOC, and even wanted to have a predictive genetic
test (96.6 %).
Conclusions: The results of this study lead to the conclusion that the current
practice of dissemination of proband-mediated information is ineﬃcient and
does not meet the needs expressed by members of high-risk cancer families for
whom preventive measures (such as clinical surveillance, prophylactic oopho-
rectomy and prophylactic mastectomy) are available. We therefore propose to
inform relevant relatives with an informative letter, without revealing any
personal genetic test results.
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P17. NEOADJUVANT HORMONAL THERAPY IN BREAST CANCER:
RESPONSE IS NOT ALWAYS REFLECTED IN A SIZE REDUCTION BY
CLINICAL EXAMINATION OR IMAGING
Ian Michiels, Cecile Colpaert, Manon Huizing, Inge Verslegers, Wiebren A.
Tjalma. University Multidisciplinary Breast Clinic Antwerp, Edegem, Belgium
Introduction: Locally advanced breast cancer treated by mastectomy is associ-
ated with a high risk of loco-regional recurrence, metastatic disease and poor
outcome. Neoadjuvant hormonal therapy is used to reduce the size of the
tumour and the number of micrometastasis, in order to improve outcome. A
reduction of tumour volume on clinical examination and imaging is generally
regarded as response.
Case report: A 69 year old woman came to the gynaecology clinic with a palpable
mass in her left breast. She was referred by the haematology department, where
she was treated for low-grade Non-Hodgkin’s lymphoma stage IV in 1993. In
1996, she experienced a mild cerebrovascular accident (CVA) and in 1999 she
was put on anti-coagulantia because of an inferior infarction of the right lung. In
2000, she developed a myelodysplastic syndrome.
Clinical examination of the left breast showed a palpable tumour with a diameter
of 6 · 3 cm in the superomedial quadrant. The left axilla contained a small
mobile lymph node.
Mammography showed a distortion of the breast tissue behind the left areola,
while ultrasound demonstrated a poorly deﬁned hypo-echogenic lesion in the left
breast together with pathologically enlarged lymph nodes in the left axilla
between 1 and 2.3 cm in diameter.
Magnetic resonance imaging (MRI) showed a zone extended over 6 cm in the
superolateral quadrant of the left breast with a pathological time–intensity
curve. A true-cut biopsy was performed and showed an inﬁltrating lobular
carcinoma with 100% oestrogen receptor-positivity, no receptors for progestogen
and overexpression of the HER2/Neu oncoprotein.
Liver ultrasound, chest X-ray and bone scintigraphy showed no indication for
metastasis. CA 15.3 levels were 25.5 /ml. Therefore, it concerned an extensive
local process (T3N1M0).
As there was an important co-morbidity in this patient, a neo-adjuvant
hormonal therapy (letrozole) was the ﬁrst choice of treatment. In case of
suﬃcient tumour regression, surgical treatment would be considered.
The patient was re-evaluated after 6 months. Breast palpation still demonstrated
the same pronounced mass superomedial in the left breast. Ultrasound still
showed an inhomogenic mass superior in the left breast and hypo-echogenic
lymph nodes with diameters between 10 and 19 mm. Mammography now
revealed a zone with relatively higher density behind the left areola and above
that a few small nodules.
MRI showed two proximate circular lesions with identical position compared
with the previous MRI, but with less captation of contrast. CA 15.3 levels were
29.1 l/ml.
Clinically speaking, there was no sense of regression of the disease and one could
say there was a certain stability. Preceded by haematological work-up, a
mastectomy of the left breast was performed followed by axillary lymph node
resection.
Pathology results showed dense ﬁbrous breast tissue with multiple foci of
inﬁltrating, well-diﬀerentiated lobular adenocarcinoma. The inﬁltrating compo-
nent was located in the 9-cm ﬁbrous zone. It was impossible to determine the
maximal tumour diameter. The M.A.I was 0. The receptor status was identical to
that in the true-cut biopsy, except for the overexpression of the HER2/Neu
oncoprotein which was no longer detectable. All six prelevated lymph nodes
were invaded by lobular adenocarcinoma without capsular penetration. There
was a remarkable amount of dense ﬁbrosis within the lymph nodes.
Although clinical examination and imaging techniques did not show any tumour
regression after neo-adjuvant treatment with letrozole, tumour load reduction
was proven by pathology reports. Because of partial response in neo-adjuvant
setting, further adjuvant treatment with letrozole was given.
Conclusions: Tumour response is not always reﬂected by a reduction in tumour
size on clinical examination or imaging (mammography or magnetic nuclear
imaging). The true response can only be assessed by pathology.
P18. IUMPA-2: PROGESTERONE RECEPTOR LEVEL IN ENDO-
METRIAL HYPERPLASIA SIMPLEX AS A PROGNOSIS FOR THE
LOCAL EFFECT OF INTRAUTERINE DRUG DELIVERY SYSTEM
Kowalski AJ, Welfel J, Suzin JI. Department of Gynaecological Oncology,
Medical University of Lodz, Lodz, Poland
Grant of The State Committee of Scientiﬁc Research nr 4P05E 058 19
Introduction: IUMPA-2 (Intrauterine Medroxy progesterone Acetate) is a drug
delivery system aimed at the local intrauterine distribution of progestagen. Its
therapeutic eﬀect is due to a well-known action of the mechanism of action of the
steroid hormone on target tissues through passive diﬀusion. The aim of this
study was to examine cytosolic progesterone receptor levels to assess the
potential eﬀect of blocking the process of oestrogen binding to the cytosolic
oestrogen receptor. The inhibition of oestrogen binding to the cytosolic
oestrogen receptor inhibits the expression of cellular DNA and subsequent
protein synthesis and, as a consequence, reduces further tissue hyperplasia.
Materials and methods: The study comprised 165 patients, divided into the
following groups:
1. Forty nine patients with uterine leiomyoma, whose endometrium was
histopathologically normal,
2. Fifty four patients, in whom simple endometrial hyperplasia was detected,
3. Sixty two patients with endometrial carcinoma.
Histological material was collected by way of a hysteroscopic-guided biopsy,
with the size of the sample set at 2 mg. In our study, we used an
immunoenzymatic method to measure the cytosolic progesterone levels, we
assessed the receptor protein level in relation to the total protein level in the
tissue examined (fmol/mg).
Results:
• Cytosolic progesterone receptor level in normal endometrium: 567.19 fmol/mg
(standard deviation (SD) 289.25).
• Cytosolic progesterone receptor level in simple endometrial hyperplasia:
614.29 fmol/mg (SD 252.31).
• Cytosolic progesterone receptor level in endometrial hyperplasia: 147.67 fmol/
mg (SD 256.19).
Discussion: The results show that progesterone receptor levels in normal
endometrium and in simple endometrial hyperplasia, are very similar. The
examined receptor level is suﬃcient grounds for the local application of
progesterone, in keeping with the rule that the higher the receptor level the better
the results of the hormonal therapy. Our results, are consistent with our
previously obtained data, as well as with data in the literature.
Conclusions: It is justiﬁed to use apply IUMPA-2 to treat endometrial
hyperplasia simplex on account of high cytosolic progesterone receptor level.
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P19. PHYTO-OESTROGENS
Jaak Ph. Janssens. MD, PhD Limburgs Universitair Centrum, University Campus
– Building C, 3590 Diepenbeek, Belgium
Phyto-oestrogens could be a valid substitute in the treatment of postmenopausal
symptoms. This suggestion is often made based on epidemiological studies and,
to a much lesser extent, based on data from mature and well-designed clinical
trials. Phyto-oestrogens have a modest activity on hot ﬂashes. The scientiﬁc
support, from mostly underpowered clinical trials, shows an improvement in
almost 40% of the patients compared with 20% placebo and 80% of oestrogen-
treated patients. The biologically eﬀective dose is in the order of 50–100 mg per
day. The eﬀect of isoﬂavones, particularly genistein, on bone mineral metabolism
is well documented, both in preclinical and clinical work. A daily dose of 50–100
mg genistein compares well with 1 mg oestradiol. The treatment with phyto-
oestrogens of both hot ﬂashes and bone demineralisation takes time: 4 months to
1 year. Isoﬂavones are well known to protect individuals from cardiovascular
diseases and the health claim of soy proteins is well documented, with sound
scientiﬁc support. The daily dose again is minimally 50 mg isoﬂavones or 25 g of
soy protein. Phyto-oestrogens are well tolerated and doses up to 300 mg daily are
non-toxic. Nutrition-derived phyto-oestrogens even protect against endometrial,
breast and colon cancers. By virtue of this wealth of qualities, phyto-oestrogens
indeed appear excellent alternatives to classic hormonal replacement therapy
when prevention of osteoporosis and cardiovascular disease is the goal. Even in
the treatment of hot-ﬂashes they can be useful. At least, that is what we can
predict from nutrition studies. Now that more puriﬁed compounds, mixtures and
extracts become available in deﬁnable quantities, it is time for clinical studies.
Then we can learn how much, when and for whom we can advise the use of
phyto-oestrogens in the future.
P20. CONCOMITANT ENDOMETRIAL AND OVARIAN HORMONE-
SENSITIVE MALIGNANCIES: A REPORT OF TWO CASES
Tijdhof Pa, Van Den Bosch Ta, Riphagen Ia, Cornelis Ab. aDepartments of
Obstetrics and Gynaecology, A.Z. Heilig Hart, Tienen, Belgium. bDepartments of
Pathology, A.Z. Heilig Hart, Tienen, Belgium
Case 1: A 71-year old patient presented with postmenopausal bleeding for more
than one year. The patient had diabetes mellitus type 2 and arterial hypertension,
was obese (body mass index (BMI) 41.74 kg/m2) and had a supernormal bone
density (Z-scores of 3.8 SD for L1-L4 and 3.6 SD for right and left hip). On
vaginal ultrasound and computerised tomographic (CT)-scan, an endometrial
thickness of 50.1 mm and a 200 x 110 x 150 mm ovarian mass above the uterus
were found. Pipelle endometrial biopsy led to the diagnosis of a well-
diﬀerentiated endometrioid adenocarcinoma. A total abdominal hysterectomy
with bilateral salpingo-ovariectomy, peritoneal washing and omentectomy were
performed. On histology, the diagnosis of an extensive grade I endometrioid
adenocarcinoma of the endometrium with superﬁcial myometrial invasion, as
well as a large unilateral stage Ia endometrioid adenocarcinoma of the left ovary
was made. There was endometriosis of the contralateral ovary.
Case 2: A 43-year old nulligravida presented with a one year history of
menometrorrhagia and dysmenorrhoea. The patient had type 2 diabetes mellitus,
was obese, and had a history of primary subfertility. Vaginal ultrasound showed
a myomatous uterus with irregular endometrial lining. A total abdominal
hysterectomy with bilateral salpingo-ovariectomy was performed. The histolog-
ical examination conﬁrmed the uterine myomata and demonstrated a well
diﬀerentiated stage Ia endometrioid adenocarcinoma of the endometrium, as
well as a unilateral Mu¨llerian stage Ia adenosarcoma of one ovary: the epithelial
component was borderline malignant and the stromal component was a low
grade sarcoma. Endometriosis in the contralateral ovary was found.
Conclusion: In both cases independent synchronous primary Mu¨llerian tumours
of the endometrium and one of the ovaries is suggested based on the clinical
presentation and the histological features. Chronic endogenous oestrogenic
impregnation may have promoted the development of both the well diﬀeren-
tiated endometrial carcinoma, and the malignant degeneration of ovarian
endometriosis.
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